Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) Meeting Abstract


Authors: Weekes, C.; Berlin, J.; Lenz, H. J.; O'Neil, B.; Messersmith, W.; Cohen, S.; Dendinger, C.; Shahda, S.; Kapoun, A.; Zhang, C.; Jenner, R.; Cattaruzza, F.; Xu, L.; Dupont, J.; Brachmann, R.; Uttamsingh, S.; Farooki, A.; Dotan, E.
Abstract Title: Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
Meeting Title: 41st European Society for Medical Oncology Congress (ESMO)
Journal Title: Annals of Oncology
Volume: 27
Issue: Suppl. 6
Meeting Dates: 2016 Oct 7-11
Meeting Location: Copenhagen, Denmark
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2016-10-01
Start Page: vi117
Language: English
ACCESSION: WOS:000393912500365
DOI: 10.1093/annonc/mdw368.10
PROVIDER: wos
Notes: Meeting Abstract: 367PD -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Azeez Farooki
    76 Farooki